Cultivating Growth
Advances in the life sciences will continue to have a far-reaching impact on virtually every aspect of our society. Safeguard recognizes the pervasive benefits of the healthcare industry and partners with companies who harness various opportunities for growth.
As our population ages, more precise and value-oriented healthcare products and services will continue to attract greater demand. Simultaneously, the life sciences industry seeks innovative ways to more accurately diagnose disease, enhance drug development pipelines, comply with regulatory requirements and increase process efficiencies. Highly-targeted treatments, derived from devices and drugs, are driving healthcare costs to new levels. And, the entire industry is under pressure to provide the highest quality medical care and treatment options while navigating various financial, governmental and logistical constraints.
Safeguard invests in growth-stage, entrepreneurial life sciences companies who have a competitive advantage in markets that represent sizable opportunities. We look for strong management teams in companies that address key strategic themes throughout our target markets.
Safeguard's Currently Portfolio of Life Sciences Partner Companies includes:
-
Advanced BioHealing, Inc.
-
Alverix, Inc.
-
Avid Radiopharmaceuticals, Inc.
-
Cellumen, Inc.
-
Clarient, Inc. (Nasdaq: CLRT)
-
Garnet BioTherapeutics, Inc.
-
Molecular Biometrics, Inc.
-
NuPathe, Inc.
-
Quinnova Pharmaceuticals, Inc.
-
Rubicor Medical, Inc.
-
Tengion, Inc.